Drugs / Gadoterate
Gadoterate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02286258 | Oct 2014 → Feb 2017 | chronic kidney disease | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03602339 | Nov 2018 → Mar 2020 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT02382380 | Nov 2014 → Mar 2024 | impaired renal function disease | Loyola University | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gadoterate | “Gadoterate” NCT03602339 ↗ |
| Known as | Clariscan | “Gadoterate (Dotarem/Clariscan)” NCT03602339 ↗ |
| Known as | Dotarem | “Gadoterate (Dotarem/Clariscan)” NCT03602339 ↗ |
| Known as | Gd-DOTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286258 ↗ |
| Modality | Diagnostic / imaging agent | “Gd-DOTA is a macrocyclic paramagnetic contrast product” NCT02286258 ↗ |
| Route | Intravenous | “Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.” NCT03602339 ↗ |